Events, By Category and Date:» Go to news main
'Fixing' the Human Genome: Promises & Pitfalls
In December 2015, an international group of experts from the National Academies of Sciences, Engineering & Medicine said “it would be irresponsible to proceed with any clinical use of germline gene editing unless and until (i) the relevant safety and efficacy issues have been resolved … and (ii) there is broad societal consensus about the appropriateness of the proposed application.” They maintained that germline gene editing raises “moral and ethical considerations in purposefully altering human evolution.” Join us for a discussion of the basic science and prospective clinical applications of gene editing as well as the legal and policy activities that advances in these technologies have triggered.
Topics for discussion will include:
- basic scientific explanation of how various gene editing technologies (including CRISPR/Cas9) work
- how these technologies give rise to new possibilities for treating and preventing diseases like cancer as well as disorders of the musculoskeletal and nervous systems
- safety-related concerns (including physical risks) of these technologies
- ethical, and specifically human flourishing, concerns regarding the potential modification of the human species now and for the future
Andrew Fenton (Research Associate, Novel Tech Ethics, Faculty of Medicine • Assistant Professor, Department of Philosophy, Dalhousie University, Halifax NS)
Graham Dallaire (Director of Research & Professor, Department of Pathology, Faculty of Medicine, Dalhousie University) studies how the cell repairs DNA damage and how cancers develop resistance to radiation and chemotherapy treatment. He obtained his Ph.D. in Experimental Medicine from McGill University in the field of genetic engineering and DNA recombination, and completed postdoctoral training at the Medical Research Council (MRC) Human Genetics Unit in Edinburgh Scotland, and the Hospital for Sick Children in Toronto, Ontario. Funded by the CIHR, Dr. Dellaire's laboratory recently developed a novel test for measuring the efficiency of CRISPR-based gene editing in living cells, and continues to use CRISPR to develop new treatments for cancer and chronic viral infections. Click here to find out more information on the Dellaire Lab, its publications, and nuclear structure and cancer biology.
Josephine Johnson is Director of Research and Research Scholar at The Hastings Center, an independent bioethics research institute in Garrison, New York. She works on a range of ethical, legal, and policy issues in science and medicine. Her current projects address the ethical implications of new kinds of prenatal genetic tests, the relationship between gene editing technologies and understandings of human flourishing, and, with colleagues at University of California, San Francisco, the potential use of genetic sequencing technology in newborns. She is also a member of Columbia University Medical Center’s Center for Excellence in Ethical, Legal and Social Implications looking at psychiatric, neurologic and behavioral genetics. Josephine is also developing a bioethics research program for high school students. Click here to find out more about Hastings Center publications & resources.
- What has yogurt got to do with human gene editing?
- How might gene editing affect competitive sports?
- If we can, shouldn't we create humans that are resistant to various cancers? Should we edit humans so that certain kinds of dis-abilities (like Down's Syndrome) become a thing of the past?
- Can we make sense of concerns about "playing God or the Goddess" in human gene editing without this being a question only relevant to theists?
- Copeland, C., & Gerrard, A. (Spring 2016). Advancing gene therapy: Dr. Graham Dellaire gains international acclaim for his CRISPR screening technology. Dalhousie Medical Research Foundation Newsletter.
- Gerrard, A. (4 Mar 2016). Dal researcher develops technique for enhancing gene therapy. Dal News.
- Hyun, I., Wilkerson, A., & Johnston, J. (12 May 2016). Embryology policy: Revisit the 14-day rule. Nature, 533:169-171.
- Johnston, J., Banerjee, M.P., & Geller, G. (28 Sept 2015). Trustworthy research institutions: The challenging case of studying the genetics of intelligence. The Hastings Center Report, 45(S1):S59-S65.
- Flatow, I. (17 May 2013). Researchers report cloning advance for producing stem cells. NPR.
- Orthwein, A., Noordermeer, S.M., Wilson, M.D., Landry, S., Enchev, R.I., Sherker, A., Munro, M., Pinder, J., Salsman, J., Dellaire, G., Xia, B., Peter, M., & Durocher, D. (17 Dec 2015). A mechanism for the suppression of homologous recombination in G1 cells. Nature, 528(7582):422-426.
- Pace, N. (3 Mar 2016). Halifax scientist's breakthrough gene work stalled by lack of funding. Global News.
- Pinder, J., Salsman, J. & Dellaire, G. (30 Oct 2015). Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Research, 43(19):9379-93992.
- Zhang, S. (1 Dec 2015). CRISPR is getting better. Now it's time to ask the hard ethical questions. Wired.
- Identity, Alzheimer's and End‑of‑life Care
- Human Nuclear Genome Transfer (So‑called Mitochondrial Replacement): Clearing the Underbrush
- Editorial Misconduct
- The Ethics of Gene Editing
- Human Gene Editing: The Dawn, the Zenith and the Dusk
- Social and Ethical Aspects of Genome Engineering
- Quality Concerns & Problems with Support for Bioethics Research
- Still Gloria: Personal Identity and Dementia